These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 23668212)

  • 1. [Clinical analysis of therapeutic impact and prognosis of autologous peripheral blood stem cell transplantation in multiple myeloma].
    Qu XY; Chen LJ; Miao KR; Zhang R; Lu RN; Liu P; Qian SX; Lu H; Qiu HX; Xu W; Wu HX; Li JY
    Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):352-4. PubMed ID: 23668212
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma.
    Korthals M; Sehnke N; Kronenwett R; Schroeder T; Strapatsas T; Kobbe G; Haas R; Fenk R
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1109-15. PubMed ID: 23644045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma patients--single center experience].
    Piatkowska-Jakubas B; Wolska-Smoleń T; Mensah-Glanowska P; Hawrylecka D; Szostek M; Walter Z; Skotnicki AB
    Przegl Lek; 2011; 68(2):78-81. PubMed ID: 21751514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation.
    Klaus J; Herrmann D; Breitkreutz I; Hegenbart U; Mazitschek U; Egerer G; Cremer FW; Lowenthal RM; Huesing J; Fruehauf S; Moehler T; Ho AD; Goldschmidt H
    Eur J Haematol; 2007 Jan; 78(1):21-8. PubMed ID: 17042762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.
    Ozaki S; Harada T; Saitoh T; Shimazaki C; Itagaki M; Asaoku H; Kuroda Y; Chou T; Yoshiki Y; Suzuki K; Murakami H; Hayashi K; Mina R; Palumbo A; Shimizu K; ;
    Acta Haematol; 2014; 132(2):211-9. PubMed ID: 24662986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of diverse high-dose regimens followed by autologous peripheral blood stem cell transplantation in consecutive multiple myeloma patients: a single-centre analysis over a 12-year period.
    Haas PS; Bauchmüller K; Kühnemund A; Finke J; Ihorst G; Engelhardt M
    Ann Hematol; 2006 Mar; 85(3):191-3. PubMed ID: 16365747
    [No Abstract]   [Full Text] [Related]  

  • 7. Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect.
    Alyea E; Weller E; Schlossman R; Canning C; Mauch P; Ng A; Fisher D; Gribben J; Freeman A; Parikh B; Richardson P; Soiffer R; Ritz J; Anderson KC
    Bone Marrow Transplant; 2003 Dec; 32(12):1145-51. PubMed ID: 14647268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.
    O'Shea D; Giles C; Terpos E; Perz J; Politou M; Sana V; Naresh K; Lampert I; Samson D; Narat S; Kanfer E; Olavarria E; Apperley JF; Rahemtulla A
    Bone Marrow Transplant; 2006 Apr; 37(8):731-7. PubMed ID: 16501593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life in multiple myeloma survivors treated with high dose chemotherapy followed by autologous peripheral blood progenitor cell transplantation: a retrospective analysis.
    Slovacek L; Slovackova B; Pavlik V; Hrstka Z; Macingova Z; Jebavy L; Horacek JM
    Neoplasma; 2008; 55(4):350-5. PubMed ID: 18505348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.
    Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S
    Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Newly diagnosed multiple myeloma: allograft or autograft?
    Gupta D; Kumar L
    Natl Med J India; 2007; 20(6):300-1. PubMed ID: 18335797
    [No Abstract]   [Full Text] [Related]  

  • 12. Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation.
    Awan FT; Osman S; Kochuparambil ST; Gibson L; Remick SC; Abraham J; Craig M; Jillella A; Hamadani M
    Bone Marrow Transplant; 2012 Jan; 47(1):146-8. PubMed ID: 21358681
    [No Abstract]   [Full Text] [Related]  

  • 13. Hemophagocytic syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma; successful treatment with high-dose intravenous immunoglobulin.
    Ostronoff M; Ostronoff F; Coutinho M; Calixto R; Souto Maior AP; Sucupira A; Florencio R; Tagliari C
    Bone Marrow Transplant; 2006 Apr; 37(8):797-8. PubMed ID: 16518425
    [No Abstract]   [Full Text] [Related]  

  • 14. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unsuccessful stem cell remobilization for autologous transplantation is predicted by renal impairment and a stem cell yield ≤ 0.5 X 10(6) CD34+ cells/kg at first mobilization.
    Hill QA; Pearce R; Cook G
    Bone Marrow Transplant; 2012 Oct; 47(10):1372-3. PubMed ID: 22343671
    [No Abstract]   [Full Text] [Related]  

  • 16. Splenic rupture following administration of pegfilgrastim in a patient with multiple myeloma undergoing autologous peripheral blood stem cell transplantation.
    Kuendgen A; Fenk R; Bruns I; Dommach M; Schutte A; Engers R; Hünerlitürkoglu A; Haas R; Kobbe G
    Bone Marrow Transplant; 2006 Jul; 38(1):69-70. PubMed ID: 16715114
    [No Abstract]   [Full Text] [Related]  

  • 17. Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation.
    Galimberti S; Benedetti E; Morabito F; Papineschi F; Callea V; Fazzi R; Stelitano C; Andreazzoli F; Guerrini F; Ciabatti E; Martino M; Nobile F; Iacopino P; Petrini M
    Leuk Res; 2005 Aug; 29(8):961-6. PubMed ID: 15978948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma.
    Harousseau JL; Attal M; Divine M; Milpied N; Marit G; Leblond V; Stoppa AM; Bourhis JH; Caillot D; Boasson M
    Bone Marrow Transplant; 1995 Jun; 15(6):963-9. PubMed ID: 7581098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brachial plexopathy following high-dose melphalan and autologous peripheral blood stem cell transplantation.
    Parrish C; Ming A; Patmore R; Shields M; Allsup D
    Bone Marrow Transplant; 2010 May; 45(5):951-2. PubMed ID: 19767786
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.